文献速递骨软组织肉瘤与黑色素瘤

III期黑色素瘤完全切除后辅助伊匹木单抗对比安慰剂的长期随访:EORTC 18071双盲III期随机试验

Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial.
PubMed 文献 · Eur J Cancer · 2019-08-07

基于EORTC 18071试验,III期皮肤黑色素瘤完全切除后辅助伊匹木单抗10 mg/kg对比安慰剂,中位OS随访6.9年。伊匹木单抗组RFS(HR 0.75,95%CI 0.63-0.88;P<0.001)、DMFS(HR 0.76,0.64-0.90;P=0.002)和OS(HR 0.73,0.60-0.89;P=0.002)获益持久,7年OS绝对差异8.7%,亚组一致。

要点

  • 辅助伊匹木单抗显著延长III期黑色素瘤完全切除后的RFS、DMFS和OS。
  • 获益持久,7年OS绝对差异8.7%,各亚组一致。
  • 因不良事件停药率伊匹木单抗组53.3% vs 安慰剂组4.6%。

核心结论

  • 辅助伊匹木单抗10 mg/kg显著延长III期皮肤黑色素瘤完全切除后的RFS、DMFS和OS,且长期持续、亚组一致。

研究设计与样本

  • EORTC 18071双盲III期随机试验,99个中心随机951例III期皮肤黑色素瘤患者(排除淋巴结转移≤1 mm或卫星转移),接受伊匹木单抗10 mg/kg或安慰剂静脉输注,每3周4剂,后每3个月至多3年。

主要发现

  • 中位OS随访6.9年,伊匹木单抗组RFS HR 0.75(95%CI 0.63-0.88;P<0.001),DMFS HR 0.76(0.64-0.90;P=0.002),OS HR 0.73(0.60-0.89;P=0.002)。
  • 7年OS绝对差异8.7%,获益在各亚组一致。
  • 因不良事件治疗终止率伊匹木单抗组53.3%,安慰剂组4.6%。

临床怎么用

  • 对于III期皮肤黑色素瘤完全切除患者,辅助伊匹木单抗10 mg/kg可带来长期RFS、DMFS和OS获益,但需注意因不良事件导致的高停药率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Since 2015, adjuvant therapy with ipilimumab is an approved treatment for stage III melanoma based on a significantly prolonged recurrence-free survival (RFS). At a median follow-up of 5.3 years, RFS, distant metastasis-free survival (DMFS) and overall survival (OS) were each significantly prolonged in the ipilimumab group compared with the placebo group, despite a 53.3% (ipilimumab) versus 4.6% (placebo) treatment discontinuation rate due to adverse events. We present now long-term follow-up results of this European Organisation for Research and Treatment of Cancer 18071 trial. PATIENTS, METHODS AND RESULTS: A total of 99 sites randomised 951 patients with stage III cutaneous melanoma (excluding lymph node metastasis ≤1 mm or in-transit metastasis) with adequate resection of lymph nodes to receive intravenous infusions of ipilimumab 10 mg/kg or placebo, every 3 weeks for 4 doses, then every 3 months for up to 3 years. The RFS, DMFS and OS, as reported by the local investigators, were assessed by the intention-to-treat analysis. Among 431 patients randomised at 63 sites and who were still alive at the analysis reported in 2016, recent follow-up information could be obtained for 264 patients. The median OS follow-up was 6.9 years. The RFS (hazard ratio [HR] 0.75, 95% confidence interval 0.63-0.88; P < 0.001), DMFS (HR 0.76, 0.64-0.90; P = 0.002) and OS (HR 0.73, 0.60-0.89; P = 0.002) benefit observed in the ipilimumab group was durable with an 8.7% absolute difference at 7 years for OS. The benefit was consistent across subgroups. CONCLUSIONS: Adjuvant therapy with ipilimumab prolongs RFS, DMFS and OS significantly. The benefit is sustained long term and consistent across subgroups.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Eggermont AMM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. Eur J Cancer. 2019. PMID: 31400634. doi:10.1016/j.ejca.2019.07.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。